



REVIEW ARTICLE

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B

T. C. NICHOLS,* R. A. RAYMER,* H. W. G. FRANCK,* E. P. MERRICKS,* D. A. BELLINGER,* N. DEFRIESS,* P. MARGARITIS,† V. R. ARRUDA,† M. A. KAY‡ and K. A. HIGH†,§

*Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; †Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, Philadelphia, PA, USA; ‡Department of Pediatrics, Program in Human Gene Therapy, Stanford University, Stanford, CA, USA; and §Department of Pediatrics, Howard Hughes Medical Institute, Philadelphia, PA, USA

Summary. Dogs with haemophilia A or haemophilia B exhibit spontaneous bleeding comparable with the spontaneous bleeding phenotype that occurs in humans with severe haemophilia. The phenotypic and genotypic characteristics of haemophilic dogs have been well-described, and such dogs are suitable for testing prophylactic protein replacement therapy and gene transfer strategies. In dogs with haemophilia, long-term effects on spontaneous bleeding frequency (measured over years) can be used as an

efficacy endpoint in such studies. Although complete correction of coagulopathy has not been achieved, published data show that prophylactic factor replacement therapy and gene transfer can markedly reduce the frequency of spontaneous bleeding in haemophilic dogs. Further studies are currently ongoing.

Keywords: dogs, haemophilia A, haemophilia B, spontaneous bleeding

Introduction

Dogs with haemophilia A or haemophilia B are severely deficient (<1% activity and antigen) in coagulation factor VIII (FVIII) or coagulation factor IX (FIX) respectively. These dogs exhibit a spontaneous bleeding phenotype that often occurs in joints and soft tissues in a manner that mimics humans with these disorders. When left untreated, the bleeding is severe, debilitating and can be fatal. Notably, mice with haemophilia tend not to have spontaneous bleeds, whereas haemophilia B dogs have a range of 4–6 spontaneous bleeds per year [1], and the frequency appears to be the same in the Chapel Hill strain of haemophilia A dogs (Tables 1 and 2) [2,3]. Thus, bleeding frequency can be used as an efficacy endpoint in studies designed to correct the haemo-

philic coagulopathy. This issue has been addressed in the haemophilic dogs both by long-term (years) prophylactic replacement with recombinant anti-haemophilic factors and by long-term expression of the missing coagulation factors or canine factor VIIa (cFVIIa) mediated by successful gene transfer. This study reviews the published data on the change in bleeding frequency using these two strategies.

Molecular defects in the Chapel Hill strain of dogs with haemophilia

Haemophilia A

Haemophilia A is an inherited X-linked disorder caused by a deficiency of FVIII. The canine factor VIII (cFVIII) cDNA sequence identity is 77–92% similar to that of humans, mice, sheep and pigs, as are the homologous A1, A2, B, A3, C1 and C2 domain structures [4]. Key functional motifs are conserved between canine and human FVIII: the von Willebrand factor binding sites, three thrombin cleavage sites, the protein C cleavage site and the six tyrosines known to be sulphated on human FVIII. While it is highly likely that the cFVIII expression is

Correspondence: Timothy C. Nichols, MD, Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, UNC School of Medicine, CB#3114, 125 University Lake Drive, Chapel Hill, NC 27516-3114, USA.
Tel.: +1 919 966 3274; fax: +1 919 966 0366;
e-mail: tnichols@med.unc.edu

Accepted after revision 1 March 2010

© 2010 The Authors
Journal Compilation © 2010 Blackwell Publishing Ltd

Table 1. Comparison of canine and murine haemophilia.

	Mice	Dogs
Factor antigen and activity	Absent	Absent
cDNAs for FVIII and FIX available	Yes	Yes
Genetic background	Outbred and inbred	Outbred
Introduce other mutations	Feasible	Difficult
Large amounts of plasma	Difficult	Yes
Life expectancy	~2 years	>10 years
Preclinical predictive accuracy	Limited data	Yes (>50 years' data)
Spontaneous bleeds	Rare	Frequent

FVIII, factor VIII; FIX, factor IX.

Table 2. Reduced incidence of spontaneous bleeding by prophylactic administration of factor IX (FIX) compared with 'on-demand' treatment in haemophilia B dogs (based on Russell *et al.* 2003 [1], with permission). This research was originally published in *Blood*. Russell KE, Olsen EHN, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immunotolerant haemophilia B dogs. *Blood* 2003; 102: 4393–8. © The American Society of Hematology.

	Bleeding events per year	
	0–1 year	1–3.5 years
Haemophilia B dogs		
On-demand (<i>n</i>)	5.5 ± 3.3 (10)	4.1 ± 3.6 (6)
Prophylactic (<i>n</i>)	1.8 ± 0.5 (5)	2.1 ± 1.0 (4)
Reduction (%)	69	49
<i>P</i> -value	0.0007	0.44

as complex as that of humans [5], very recently recombinant cFVIII was produced and shown to be safe and efficacious in haemophilia A dogs in short-term studies [6]. Using the cFVIII cDNA, researchers found that both the Chapel Hill and Queen's University (Ontario, Canada) strains of haemophilia A dogs have an intron 22 inversion [3,7]. This defect faithfully replicates a causative mutation present in about 40% of humans with severe haemophilia A [8–10].

Haemophilia B

Haemophilia B is an inherited X-linked disorder caused by a deficiency of FIX. The canine factor IX (cFIX) cDNA is 86% conserved at the amino acid level when compared with human FIX [11]. The leader peptide, Gla domain, epidermal growth factor (EGF) domains and carboxy-terminal portion of the heavy chain all have extensive sequence conservation between dogs and humans. All glutamic acid (Glu)

residues undergoing gamma-carboxylation in humans are conserved in cFIX. This 1989 description of cFIX cDNA provided the necessary tools for identification of the molecular defects in several strains of haemophilia B dogs [12–15]. Two strains have been used extensively in gene therapy studies: one with a deletion mutation in Lhasa Apso dogs that are prone to develop inhibitory antibodies to infused cFIX [14] and the other with a missense mutation that does not develop inhibitory antibodies to infused cFIX, and this latter group has been maintained in Chapel Hill since 1966 [12].

The well-described phenotypes and genotypes of these haemophilia A and haemophilia B dogs make them very desirable for studying the pathophysiology of haemophilia and for testing replacement therapies and gene therapy strategies.

Prophylactic FIX replacement therapy in canine haemophilia B

To determine whether prophylactic replacement of FIX would reduce bleeding frequency in haemophilia B dogs, a group of littermates were immunologically tolerized to recombinant human FIX and then tolerized prophylactically to achieve trough levels of ~1% and a shortened whole blood clotting time (WBCT). Compared with nontolerized haemophilia B dogs in the Chapel Hill colony monitored concurrently and treated 'on-demand', the tolerized dogs had a reduction in spontaneous bleeding over 3.5 years [69% during the first year of life (*P* = 0.0007); 49% between years 1 and 3.5 (*P* = 0.44); Table 2] [1]. The reduction in bleeding frequency between years 1 and 3.5 did not achieve statistical significance because of the small numbers of animals; nonetheless, 49% less bleeding events would be a considerable clinical improvement in any species. At the target level of ~1% of normal FIX, these dogs enjoyed a marked reduction in clinical bleeding; however, they still bled. Although likely, it is unknown if a higher trough level would have supported a greater reduction or ablation of bleeding in these haemophilia B dogs. Most importantly, these data establish that prophylactic administration of FIX reduces the frequency of bleeding in haemophilia B dogs.

Gene transfer in canine haemophilia A and haemophilia B

In a series of published studies, continuous expression of cFVIII [16] and cFIX [17–21] in haemophilia A and haemophilia B dogs respectively, and cFVIIIa

[2] in both haemophilia A and haemophilia B dogs, has been achieved following successful gene transfer. The data, as reported in the original publication (vector, route of administration, vector dose, duration of follow-up, WBCT, factor levels and bleeding frequencies), are summarized in Table 3. The WBCT was shortened in the haemophilia A and B dogs expressing cFVIII and cFIX respectively, and thromboelastography parameters were corrected by cFVIIa (not shown) [2]. Also, a wide range of the respective factor levels was achieved in these studies (from ~1 to 100%). Most importantly, the bleeding frequen-

cies showed that most, but not all, dogs had a marked reduction in bleeding frequency over several years when compared with the range of 4–6 bleeds per year reported for haemophilia A and B dogs treated ‘on-demand’. Five dogs that did not exhibit a persistent reduction in bleeding following publication of the initial gene transfer have been treated with alternative gene transfer strategies in attempts to reduce their bleeding frequencies (dogs B46, B93, B85, D31 and D32; studies in progress). In addition, dog E59 was treated by an alternative strategy, attempting to achieve a higher level of FIX produc-

Table 3. Bleeding frequencies in haemophilia A and haemophilia B dogs from published gene transfer studies.

Dog	A/B	M/F	Vector	Route	Vector dose	Months follow-up	WBCT (min)	cFIX, cFVIII, or cFVIIa	Bleeds per year post gene transfer
1. Herzog <i>et al.</i> 1999 [17]									
B45	B	M	AAV-2-CMV-cFIX	i.m.	1.3×10^{11} vp kg ⁻¹	16	20 ± 5	2.6 ± 0.7	0.3
B46	B	M	AAV-2-CMV-cFIX	i.m.	1.1×10^{12} vp kg ⁻¹	14	20 ± 2.5	12 ± 2	1.8
B93	B	M	AAV-2-CMV-cFIX	i.m.	3×10^{12} vp kg ⁻¹	12	15 ± 1.5	21 ± 2	0.3
B48	B	F	AAV-2-CMV-cFIX	i.m.	3.4×10^{12} vp kg ⁻¹	12.5	16 ± 1.5	17 ± 2	0.2
B85	B	F	AAV-2-CMV-cFIX	i.m.	8.5×10^{12} vp kg ⁻¹	11	17 ± 2	69 ± 6	0.5
2. Snyder <i>et al.</i> 1999 [18]									
B84	B	F	AAV2-MFG-cFIX	PV	2×10^{12} vp	4	12–20	30–95	0
B89	B	M	AAV2-MFG-cFIX	PV	2×10^{12} vp	4	10–25	10–45	0.25
3. Mount <i>et al.</i> 2002 [19]									
E34	B	F	AAV2-hAAT-cFIX	PV	8.0×10^{11} vg kg ⁻¹	12	11 ± 2.5	262 ± 92	0.1
4. Arruda <i>et al.</i> 2004 [20]									
E57	B	M	AAV-1 CMV PK9	i.m.	2.4×10^{11} vg kg ⁻¹	33	18.1*	104	0.1
E35	B	F	AAV-1-CMV-PK9	i.m.	1×10^{12} vg kg ⁻¹	9.5	19.1*	87	0.1
D31	B	F	AAV-2-CMV-cFIX	i.m.	8.5×10^{12} vg kg ⁻¹	27	18.4	39	0.02
D32	B	M	AAV-2-CMV-cFIX	i.m.	5.6×10^{12} vg kg ⁻¹	30.5	17	40	0.1
B14	B	M	AAV-2-CMV-cFIX	i.m.	1.1×10^{13} vg kg ⁻¹	39.5	21.2*	30	0.1
5. Arruda <i>et al.</i> 2005 [21]									
F57	B	M	AAV2-CMV-cFIX	ILP	1.7×10^{12} vg kg ⁻¹	27	18.2	260 ± 52	0.04
D99	B	F	AAV2-CMV-cFIX	ILP	3.7×10^{12} vg kg ⁻¹	39	13.9	730 ± 60	0.08
H08	B	M	AAV2-CMV-cFIX	ILP	3.0×10^{12} vg kg ⁻¹	8	19.9	210 ± 16	0.1
E60	B	F	AAV2-CMV-cFIX	ILP	3.9×10^{12} vg kg ⁻¹	10	16.3	<1–100	0.3
E59	B	F	AAV2-CMV-cFIX	i.v.	2.9×10^{12} vg kg ⁻¹	37	16.8	31–78	0.03
6. Xu <i>et al.</i> 2005 [16]									
H22	A	F	RVhAAT-cFVIII-WPRE	i.v.	$\sim 0.8 \times 10^{10}$ TU kg ⁻¹	16	9.7	101 ± 4%	0
H18	A	M	RVhAAT-cFVIII-WPRE	i.v.	$\sim 0.8 \times 10^{10}$ TU kg ⁻¹	16	9.8	129 ± 7%	0
7. Margaritis <i>et al.</i> 2009 [2]									
J10	B	M	AAV8-hAAT-cFVIIa	PV	2.06×10^{13} vg kg ⁻¹	34	37.8	≤0.5	0
J55	A	M	AAV8-hAAT-cFVIIa	PV	6.25×10^{13} vg kg ⁻¹	18	26.2	1.3–2.6	0
J57	A	F	AAV8-hAAT-cFVIIa	PV	1.25×10^{14} vg kg ⁻¹	15	23.9	1.3–2.6	0
E66	A	M	AAV8-hAAT-cFVIIa	PV	1.25×10^{14} vg kg ⁻¹	12	29.8	1.3–2.6	0

A/B, haemophilia A or haemophilia B genotype; M/F, male/female; Vector: AAV-n, adeno-associated virus (and n refers to serotype number); cFVIIa, canine factor VIIa; cFVIII, canine factor VIII; cFIX, canine factor IX; CMV, cytomegalovirus promoter; hAAT, human alpha-1-antitrypsin promoter; MFG, viral MFG promoter; RV, retrovirus; WPRE, woodchuck post-transcriptional regulatory element; Route: ILP, isolated limb perfusion; i.m., intramuscular; i.v., intravenous; PV, portal vein; Vector dose: TU, transducing units; vg, vector genomes; vp, vector particles; WBCT, whole blood clotting time.

cFIX in ng mL⁻¹ (in 1, 2, 3, 4 and 5), cFVIII as percentage of normal (in 6), or cFVIIa µg mL⁻¹ (in 7).

*Values before these dogs developed inhibitory antibodies to canine FIX at which time their WBCT was >60.

tion (study in progress). Thus, the severe spontaneous bleeder phenotype coupled with a significantly longer lifespan of dogs when compared with mice (>10 years vs. ~2 years; Table 1) allows for assessment of the degree of phenotypic correction, including monitoring for the clinically relevant endpoint of reduction in spontaneous bleeds.

Discussion

Antihæmophilic replacement products are often tested in hæmophilic dogs during short-term (1–2 weeks) infusion studies to document pharmacokinetic parameters and the degree of correction of the hæmophilic coagulopathy that can be achieved. This short-term study design models ‘on-demand’ therapy and does not address the clinically relevant endpoint of reduction in spontaneous bleeding frequency. In contrast, prophylactic administration of the missing coagulation protein or continuous expression following gene transfer allows for determining the effect on bleeding frequencies over years. When trough FIX levels were maintained at ~1% with prophylactic FIX administration, a significant but not complete reduction in bleeding frequency was achieved. A higher trough level may provide greater protection from spontaneous bleeding. Likewise, continuous expression of antihæmophilic factors following gene transfer was accompanied by a marked reduction in bleeding frequency, but did not provide complete correction. The advantage of gene therapy is that many different vectors and routes of administration are being developed. These are now being exploited to determine whether additional treatments with alternative gene therapy strategies will ameliorate spontaneous bleeding if the first gene transfer approach is unsuccessful or has limited success.

Although short-term (2-week) pharmacokinetic and pharmacodynamic infusion studies with antihæmophilic factors are not designed to address reduction in bleeding frequency, the results have nonetheless been of considerable interest and importance. Indeed, early studies with plasma products established the basis for such replacement therapy in dogs and humans with hæmophilia [22–24]. When human plasma-derived and recombinant FVIIa [25], FVIII [26–28] and FIX [29] replacement products are tested in the hæmophilia A and B dogs and shown to be safe and to correct the hæmophilic coagulopathy, these products have consistently proven to be safe and efficacious in humans, with comparable pharmacokinetics. Likewise, the recently produced recombinant cFVIII [6] has provided outstanding

haemostasis in the Chapel Hill hæmophilia A dogs in spontaneous, traumatic and surgical bleeding without inducing immune responses (Valder R. Arruda, Katherine A. High, Timothy C. Nichols personal communication). The positive predictive accuracy of these studies is a major strength of performing such studies in dogs in comparison with other species (Table 1). Consequently, many advisory boards strongly encourage investigators contemplating new therapies for hæmophilia A and hæmophilia B to demonstrate safety and efficacy in bleeder dogs before initiating studies in humans [30] [Recommendations #137 and #160 of the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation of the United States [31]].

Spontaneous bleeding has been a recognized phenotype in humans with severe hæmophilia from its earliest descriptions [32]. A comparable severe phenotype with spontaneous bleeding is present in the Chapel Hill strain of hæmophilia A and hæmophilia B dogs. Careful monitoring of these dogs for spontaneous bleeding is essential for their survival and has provided a valuable endpoint for assessing the success and limitations of prophylactic protein replacement therapy and gene transfer studies.

Acknowledgements

This work was supported by NIH grants HL063098 to Timothy C. Nichols, HL64274 to Mark A. Kay and P01 HL074124 to Katherine A. High.

Disclosures

Dr Nichols has acted as an unrestricted speaker and received honoraria from Novo Nordisk. Dr High has acted as a consultant for Novo Nordisk.

References

- 1 Russell KE, Olsen EHN, Raymer RA *et al.* Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. *Blood* 2003; **102**: 4393–8.
- 2 Margaritis P, Roy E, Aljamali MN *et al.* Successful treatment of canine hemophilia by continuous expression of canine FVIIa. *Blood* 2009; **113**: 3682–9.
- 3 Lozier JN, Dutra A, Pak E *et al.* The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. *Proc Natl Acad Sci USA* 2002; **99**: 12991–6.
- 4 Cameron C, Notley C, Hoyle S *et al.* The canine factor VIII cDNA and 5' flanking sequence. *Thromb Haemost* 1998; **79**: 317–22.
- 5 Miao HZ, Sirachainan N, Palmer L *et al.* Bioengineering of coagulation factor VIII for improved secretion. *Blood* 2004; **103**: 3412–9.

- 6 Sabatino DE, Furlan Freguia C, Toso R *et al.* Recombinant canine B-domain deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. *Blood* 2009; **114**: 4562–5.
- 7 Hough C, Kamisue S, Cameron C *et al.* Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. *Thromb Haemost* 2002; **87**: 659–65.
- 8 Antonarakis SE. Molecular genetics of coagulation factor VIII gene and hemophilia A. *Thromb Haemost* 1995; **74**: 322–8.
- 9 Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe hemophilia A. *Nat Genet* 1993; **5**: 236–41.
- 10 Naylor J, Brinke A, Hassock S, Green PM, Giannelli F. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. *Hum Mol Genet* 1993; **2**: 1773–8.
- 11 Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. Molecular cloning of a cDNA encoding canine factor IX. *Blood* 1989; **74**: 207–12.
- 12 Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. *Proc Natl Acad Sci USA* 1989; **86**: 10095–9.
- 13 Gu W, Brooks M, Catalfamo J, Ray J, Ray K. Two distinct mutations cause severe hemophilia B in two unrelated canine pedigrees. *Thromb Haemost* 1999; **82**: 1270–5.
- 14 Mauser AE, Whitlark J, Whitney KM, Lothrop CD Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs. *Blood* 1996; **88**: 3451–5.
- 15 Brooks MB, Gu W, Ray K. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B. *J Am Vet Med Assoc* 1997; **211**: 1418–21.
- 16 Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. *Proc Natl Acad Sci USA* 2005; **102**: 6080–5.
- 17 Herzog RW, Yang EY, Couto LB *et al.* Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. *Nat Med* 1999; **5**: 56–63.
- 18 Snyder RO, Miao C, Meuse L *et al.* Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. *Nat Med* 1999; **5**: 64–70.
- 19 Mount JD, Herzog RW, Tillson DM *et al.* Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. *Blood* 2002; **99**: 2670–6.
- 20 Arruda VR, Schuettrumpf J, Herzog RW *et al.* Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. *Blood* 2004; **103**: 85–92.
- 21 Arruda VR, Stedman HH, Nichols TC *et al.* Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. *Blood* 2005; **105**: 3458–64.
- 22 Brinkhous KM, Penick GD, Langdell RD, Wagner RH, Graham JB. Physiologic basis of transfusion therapy in hemophilia. *Arch Pathol* 1956; **61**: 6–10.
- 23 Wagner RH, Langdell RD, Richardson BA, Farrell RA, Brinkhous KM. Antihemophilic factor (AHF): plasma levels after administration of AHF preparations to hemophilic dogs. *Proc Soc Exp Biol Med* 1957; **96**: 152–5.
- 24 Roberts HR, Penick GD, Brinkhous KM. Intensive plasma therapy in the hemophilias. *JAMA* 1964; **190**: 546–8.
- 25 Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. *Proc Natl Acad Sci USA* 1989; **86**: 1382–6.
- 26 Brinkhous KM, Shanbrom E, Roberts HR, Webster WP, Fekete L, Wagner RH. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. *JAMA* 1968; **205**: 613–7.
- 27 Brinkhous KM, Sandberg H, Garris JB *et al.* Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. *Proc Natl Acad Sci USA* 1985; **82**: 8752–6.
- 28 Brinkhous KM, Sandberg H, Widlund L *et al.* Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. *Semin Thromb Hemost* 2002; **28**: 269–72.
- 29 Brinkhous KM, Sigman JL, Read MS *et al.* Recombinant human factor IX: replacement therapy, prophylaxis and pharmacokinetics in canine hemophilia B. *Blood* 1996; **88**: 2603–10.
- 30 Nichols TC, Dillow AM, Franck HWG *et al.* Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency. *ILAR J* 2009; **50**: 144–67.
- 31 National Hemophilia Foundation. MASAC Treatment Recommendations. Available at http://www.hemophilia.org/research/masac/masac_all.htm Accessed January 6, 2010.
- 32 Nichols WL, Bowie EJW, eds. *A History of Blood Coagulation*. Rochester, MN: Mayo Foundation for Medical Education and Research, 2001.